866-997-4948(US-Canada Toll Free)

Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Cancer

No. of Pages : 220 Pages


Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H2 2012

Global Markets Directs, 'Bile Duct Cancer (Cholangiocarcinoma)Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma). Bile Duct Cancer (Cholangiocarcinoma)Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma).
  • A review of the Bile Duct Cancer (Cholangiocarcinoma)products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bile Duct Cancer (Cholangiocarcinoma)pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma)pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bile Duct Cancer (Cholangiocarcinoma) Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) 10
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Development by Companies 12
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Pre-Clinical Stage Products 23
Comparative Analysis 23
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Products under Development by Companies 24
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Products under Investigation by Universities/Institutes 25
Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development 32
AstraZeneca PLC 32
Novartis AG 33
Access Pharmaceuticals, Inc. 34
Karo Bio 35
Marshall Edwards, Inc. 36
OncoTherapy Science, Inc. 37
Simcere Pharmaceutical Group 38
Provecs Medical GmbH 39
Mebiopharm Co., Ltd. 40
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
vandetanib - Drug Profile 47
Im-01 - Drug Profile 49
ARRY-162 - Drug Profile 51
Triphendiol - Drug Profile 53
elpamotide - Drug Profile 54
Gemcitabine + Cisplatin - Drug Profile 55
chloroquine - Drug Profile 56
erlotinib hydrochloride - Drug Profile 57
Gemcitabine + Oxaliplatin + Erlotinib - Drug Profile 59
Oxaliplatin + Erlotinib + Gemcitabine - Drug Profile 61
Irinotecan + Oxaliplatin - Drug Profile 63
Capecitabine + Epirubicin + Carboplatin - Drug Profile 64
Gemcitabine + Radiation Therapy - Drug Profile 66
stakel - Drug Profile 68
gemcitabine - Drug Profile 69
sorafenib tosylate - Drug Profile 70
Panitumumab + Gemcitabine + Oxaliplatin - Drug Profile 71
sunitinib malate - Drug Profile 73
capecitabine - Drug Profile 74
selumetinib sulfate - Drug Profile 75
temoporfin - Drug Profile 76
Gemcitabine + Capecitabine - Drug Profile 77
Erlotinib + Gemcitabine + Oxaliplatin - Drug Profile 78
Lapatinib - Drug Profile 80
Bevacizumab + Erlotinib Hydrochloride - Drug Profile 81
Gemcitabine + Cisplatin - Drug Profile 83
dolastatin 10 - Drug Profile 84
Capecitabine + Gemcitabine + Radiation Therapy - Drug Profile 85
trastuzumab - Drug Profile 87
Gemcitabine + Capecitabine - Drug Profile 88
Gemcitabine + Oxaliplatin + Sorafenib - Drug Profile 89
Zactima + Gemzar - Drug Profile 90
Tumor Infiltrating Lymphocytes + Cyclophosphamide + Fludarabine + Aldesleukin - Drug Profile 92
Gemcitabine + Cisplatin + Sorafenib - Drug Profile 94
Gemcitabine + 5-Fluorouracil + Radiation Therapy - Drug Profile 95
Gemcitabine + Cisplatin + S-1 - Drug Profile 97
gemcitabine - Drug Profile 99
Gemcitabine + Sorafenib - Drug Profile 100
S-1 + Photodynamic Therapy - Drug Profile 101
S-1 + Cisplatin - Drug Profile 102
Gemcitabine + Irinotecan + Panitumumab - Drug Profile 104
Oxaliplatin + Capecitabine + Sorafinib - Drug Profile 105
gemcitabine - Drug Profile 106
Gemzar + Taxotere - Drug Profile 107
Eloxatin + Xeloda - Drug Profile 108
Gemcitabine + Docetaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile 109
Bevacizumab + Erlotinib - Drug Profile 111
S-1 + Gemcitabine - Drug Profile 112
Cancer Specific Antigen-Derived Peptide Vaccine + Gemcitabine - Drug Profile 113
Gemcitabine + Cisplatinnn - Drug Profile 114
fluorouracil - Drug Profile 116
TS-1 + Gemcitabine - Drug Profile 117
Capecitabine + Oxaliplatin - Drug Profile 118
everolimus - Drug Profile 119
Gemcitabine + Oxaliplatin + Capecitabine - Drug Profile 120
GEMOX - Drug Profile 121
Gemcitabine + Cisplatin - Drug Profile 122
HLA-A 2402 Restricted A2691N Peptide + D0006 Peptide + F2861 Peptide + Montanide ISA-51 - Drug Profile 123
Gemcitabine + Radiation Therapy - Drug Profile 124
Gemcitabine + Cisplatin - Drug Profile 125
Gemcitabine + Cisplatin - Drug Profile 126
tegafur + gimeracil + oteracil potassium - Drug Profile 127
tegafur + gimeracil + oteracil potassium - Drug Profile 128
Gemcitabine + Radiation Therapy - Drug Profile 129
gemcitabine - Drug Profile 130
Irinotecan + Gemcitabine - Drug Profile 131
Gemcitabine + TS-1 - Drug Profile 132
Gemcitabine + Cisplatin - Drug Profile 133
cisplatin - Drug Profile 134
Epirubicin + Carboplatin + Capecitabine - Drug Profile 135
mFOLFOX - Drug Profile 137
Gemox - Drug Profile 138
UFT + Leucovorin - Drug Profile 139
Gemcitabine + S-1 - Drug Profile 141
gemcitabine - Drug Profile 142
Glivec + 5-Fluorouracil + Leucovorin - Drug Profile 143
Fludarabine + Cyclophosphamide + CD8+ Enriched TIL + Aldesleukin - Drug Profile 144
Gecitabine + Cisplatin + S-1 - Drug Profile 146
SOX - Drug Profile 148
gemcitabine - Drug Profile 149
Gemcitabine + Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile 150
Gemcitabine + Oxaliplatin + Capecitabine + Panitumumab - Drug Profile 152
5-Fluorouracil + Leucovorin + Oxaliplatin - Drug Profile 154
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 156
Gemcitabine + TS-1 - Drug Profile 157
Gemcitabine + Capecitabine - Drug Profile 158
Gemcitabine + Oxaliplatin - Drug Profile 160
porfimer sodium - Drug Profile 161
Gemcitabine - Drug Profile 162
Cetuximab + Gemcitabine + Oxaliplatin - Drug Profile 163
Modified FOLFOX6 + AZD2171 - Drug Profile 164
Docetaxel + Oxaliplatin - Drug Profile 166
Cisplatin + Gemcitabine + Selumetinib - Drug Profile 167
KB-9520 - Drug Profile 168
gemcitabine - Drug Profile 169
S-1 + Oxaliplatin - Drug Profile 170
gemcitabine - Drug Profile 172
tegafur + gimeracil + oteracil potassium - Drug Profile 173
ABT-888 + Cisplatin + Gemcitabine Hydrochloride - Drug Profile 174
GEMOX + Cetuximab - Drug Profile 176
Cisplatin + Gemcitabine + Panitumumab - Drug Profile 178
Gemcitabine + Cisplatin + S-1 - Drug Profile 179
Gemcitabine + Cisplatin - Drug Profile 180
Gemcitabine + Cisplatin + Carboplatin + Capecitabine + 5-Fluorouracil + Radiation Therapy - Drug Profile 181
Gemox 85 - Drug Profile 183
Oxaliplatin + Gemcitabine + Radiation Therapy - Drug Profile 184
WT1 Peptide Vaccination + Gemcitabine + Cisplatin - Drug Profile 185
FOLFOXIRI - Drug Profile 186
Gemcitabine + Cisplatin + S-1 - Drug Profile 188
Gemcitabine + S-1 - Drug Profile 190
gemcitabine - Drug Profile 191
imatinib mesylate - Drug Profile 192
ProLindac + Gemcitabine - Drug Profile 194
Cisplatin + 5-Fluorouracil + Gemcitabine - Drug Profile 195
JP-1584 - Drug Profile 197
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Drug Profile Updates 198
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Discontinued Products 203
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Dormant Products 204
Bile Duct Cancer (Cholangiocarcinoma) Product Development Milestones 208
Featured News & Press Releases 208

Appendix 211
Methodology 211
Coverage 211
Secondary Research 211
Primary Research 211
Expert Panel Validation 211
Contact Us 212
Disclaimer 212

List of Table


Number of Products Under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2012 18
Products under Development for Bile Duct Cancer (Cholangiocarcinoma) Comparative Analysis, H2 2012 19
Number of Products under Development by Companies, H2 2012 21
Number of Products under Investigation by Universities/Institutes, H2 2012 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 27
Comparative Analysis by Late Stage Development, H2 2012 28
Comparative Analysis by Mid Clinical Stage Development, H2 2012 29
Comparative Analysis by Early Clinical Stage Development, H2 2012 30
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 31
Products under Development by Companies, H2 2012 32
Products under Investigation by Universities/Institutes, H2 2012 33
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 34
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 39
AstraZeneca PLC, H2 2012 40
Novartis AG, H2 2012 41
Access Pharmaceuticals, Inc., H2 2012 42
Karo Bio, H2 2012 43
Marshall Edwards, Inc., H2 2012 44
OncoTherapy Science, Inc., H2 2012 45
Simcere Pharmaceutical Group, H2 2012 46
Provecs Medical GmbH, H2 2012 47
Mebiopharm Co., Ltd., H2 2012 48
Assessment by Monotherapy Products, H2 2012 49
Assessment by Combination Products, H2 2012 50
Assessment by Stage and Route of Administration, H2 2012 52
Assessment by Stage and Molecule Type, H2 2012 54
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Drug Profile Updates 206
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Discontinued Products 211
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Dormant Products 212
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Dormant Products (Contd..1) 213
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Dormant Products (Contd..2) 214
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Dormant Products (Contd..3) 215

List of Chart


Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2012 18
Products under Development for Bile Duct Cancer (Cholangiocarcinoma) Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 22
Late Stage Products, H2 2012 28
Mid Clinical Stage Products, H2 2012 29
Early Clinical Stage Products, H2 2012 30
Pre-Clinical Stage Products, H2 2012 31
Assessment by Monotherapy Products, H2 2012 49
Assessment by Combination Products, H2 2012 50
Assessment by Route of Administration, H2 2012 51
Assessment by Stage and Route of Administration, H2 2012 52
Assessment by Molecule Type, H2 2012 53
Assessment by Stage and Molecule Type, H2 2012 54

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *